Michael Weichenthal

Prof. Michael Weichenthal

Christian Albrechts University Kiel, Skin Cancer Center
orcid

Research Focus & Metrics

Academic Career Length

36Years (1991-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
22 September 2006 in Archives of Dermatological Research
Verified
Journal Article
Closed access
PDF file
DSDorothea M. Sommer
Dorothea M. Sommer
SJStefan Jenisch
Stefan Jenisch
MSMichael Suchan
Michael Suchan
ECEnno Christophers
Enno Christophers
MWMichael Weichenthal
Michael Weichenthal

24 May 2017 in Nature Communications
Verified
Journal Article
Open access
PDF file
LTLam Tsoi
Lam Tsoi
PSPhilip E. Stuart
Philip E. Stuart
CTChao Tian
Chao Tian
JGJohann E. Gudjonsson
Johann E. Gudjonsson
SDSayantan Das
Sayantan Das
JEJames T Elder
James T Elder
Psoriasis is a complex disease of skin with a prevalence of about 2%. We conducted the largest meta-analysis of genome-wide association studies (GWAS) for psoriasis to date, including data from eight different Caucasian cohorts, with a combined effective sample size >39,000 individuals. We identified 16 additional psoriasis susceptibility loci achieving genome-wide significance, increasing the number of identified loci to 63 for European-origin individuals. Functional analysis highlighted the roles of interferon signalling and the NFκB cascade, and we showed that the psoriasis signals are enriched in regulatory elements from different T cells (CD8+T-cells and CD4+T-cells including TH0, TH1 and TH17). The identified loci explain ∼28% of the genetic heritability and generate a discriminatory genetic risk score (AUC=0.76 in our sample) that is significantly correlated with age at onset (p=2 × 10−89). This study provides a comprehensive layout for the genetic architecture of common variants for psoriasis.

17 October 2010 in Nature Genetics
Verified
Journal Article
Closed access
PDF file
EEEva Ellinghaus
Eva Ellinghaus
DEDavid Ellinghaus
David Ellinghaus
PSPhilip E Stuart
Philip E Stuart
RNRajan P Nair
Rajan P Nair
SDSophie Debrus
Sophie Debrus
AFAndre Franke
Andre Franke

1 July 2008 in Journal of Investigative Dermatology
Verified
Journal Article
Open access
PDF file
RNRajan P. Nair
Rajan P. Nair
ARAndreas Ruether
Andreas Ruether
PSPhilip E. Stuart
Philip E. Stuart
SJStefan Jenisch
Stefan Jenisch
TTTrilokraj Tejasvi
Trilokraj Tejasvi
MWMichael Weichenthal
Michael Weichenthal
Psoriasis is a common inflammatory and hyperproliferative skin disease with a multifactorial genetic basis. A recent study reported that psoriasis was associated with the IL12B haplotype rs3212227 (3′-untranslated region)–rs6887695 (60 kb, 5′) and the IL23R haplotype rs7530511 (L310P)–rs11209026 (Q381R). We examined these four single-nucleotide polymorphisms (SNPs) for association with psoriasis in two groups of North American and German Caucasians: (1) 1,810 cases and 2,522 controls; and (2) 509 pedigrees. Both IL12B markers showed highly significant association with psoriasis in the case–control (rs3212227, odds ratio (OR)=1.62, P=1.7 × 10−15; rs6887695, OR=1.49, P=2.7 × 10−15) and in the family-based analysis (rs3212227, P=2.2 × 10−3; rs6887695, P=1.7 × 10−3). The IL23R SNPs also showed significant association in the cases and controls (rs7530511, OR=1.22, P=3.9 × 10−3; rs11209026, OR=1.40, P=3.8 × 10−4). For both genes, common risk haplotypes were identified whose statistical significance approached (IL23R) or exceeded (IL12B) genome-wide criteria. We found no statistical evidence for interactions of these haplotypes with HLA-Cw6. Our results confirm associations between IL12B and IL23R and psoriasis in Caucasians, and provide a genetic basis for the clinical association between psoriasis and Crohn's disease. JID JOURNAL CLUB ARTICLE: For questions, answers, and open discussion about this article please go to http://network.nature.com/group/jidclub

9 October 2018 in Nature Communications
Verified
Journal Article
Open access
PDF file
MPMatthew T. Patrick
Matthew T. Patrick
PSPhilip E. Stuart
Philip E. Stuart
KRKalpana Raja
Kalpana Raja
JGJohann E. Gudjonsson
Johann E. Gudjonsson
TTTrilokraj Tejasvi
Trilokraj Tejasvi
LTLam Tsoi
Lam Tsoi
Psoriatic arthritis (PsA) is a complex chronic musculoskeletal condition that occurs in ~30% of psoriasis patients. Currently, no systematic strategy is available that utilizes the differences in genetic architecture between PsA and cutaneous-only psoriasis (PsC) to assess PsA risk before symptoms appear. Here, we introduce a computational pipeline for predicting PsA among psoriasis patients using data from six cohorts with >7000 genotyped PsA and PsC patients. We identify 9 new loci for psoriasis or its subtypes and achieve 0.82 area under the receiver operator curve in distinguishing PsA vs. PsC when using 200 genetic markers. Among the top 5% of our PsA prediction we achieve >90% precision with 100% specificity and 16% recall for predicting PsA among psoriatic patients, using conditional inference forest or shrinkage discriminant analysis. Combining statistical and machine-learning techniques, we show that the underlying genetic differences between psoriasis subtypes can be used for individualized subtype risk assessment.

1 April 2022 in Journal of Clinical Oncology
Verified
Journal Article
Closed access
ISInês Pires da Silva
Inês Pires da Silva
TATasnia Ahmed
Tasnia Ahmed
JMJennifer L. McQuade
Jennifer L. McQuade
CNCaroline A. Nebhan
Caroline A. Nebhan
JPJohn J. Park
John J. Park
AMAlexander M. Menzies
Alexander M. Menzies
PURPOSE: Currently, there are no robust biomarkers that predict immunotherapy outcomes in metastatic melanoma. We sought to build multivariable predictive models for response and survival to anti-programmed cell death protein 1 (anti–PD-1) monotherapy or in combination with anticytotoxic T-cell lymphocyte-4 (ipilimumab [IPI]; anti–PD-1 ± IPI) by including routine clinical data available at the point of treatment initiation. METHODS: One thousand six hundred forty-four patients with metastatic melanoma treated with anti–PD-1 ± IPI at 16 centers from Australia, the United States, and Europe were included. Demographics, disease characteristics, and baseline blood parameters were analyzed. The end points of this study were objective response rate (ORR), progression-free survival (PFS), and overall survival (OS). The final predictive models for ORR, PFS, and OS were determined through penalized regression methodology (least absolute shrinkage and selection operator method) to select the most significant predictors for all three outcomes (discovery cohort, N = 633). Each model was validated internally and externally in two independent cohorts (validation-1 [N = 419] and validation-2 [N = 592]) and nomograms were created. RESULTS: The final model for predicting ORR (area under the curve [AUC] = 0.71) in immunotherapy-treated patients included the following clinical parameters: Eastern Cooperative Oncology Group Performance Status, presence/absence of liver and lung metastases, serum lactate dehydrogenase, blood neutrophil-lymphocyte ratio, therapy (monotherapy/combination), and line of treatment. The final predictive models for PFS (AUC = 0.68) and OS (AUC = 0.77) included the same variables as those in the ORR model (except for presence/absence of lung metastases), and included presence/absence of brain metastases and blood hemoglobin. Nomogram calculators were developed from the clinical models to predict outcomes for patients with metastatic melanoma treated with anti–PD-1 ± IPI. CONCLUSION: Newly developed combinations of routinely collected baseline clinical factors predict the response and survival outcomes of patients with metastatic melanoma treated with immunotherapy and may serve as valuable tools for clinical decision making.